Back to portfolio
This project centers on the validation of 5-oxo-ETE as an important mediator of eosinophilic inflammation. This program is a collaboration between Dr William Powell from the Meakins-Christie Research Institute (McGill University), and Dr. Joe Rokach from the Florida Institute of Technology. Picomolar, orally-available antagonists have been discovered and shown to block eosinophil infiltration into sites of inflammation in non-human primate models of asthma. This program has been spun out into Fairhaven Pharmaceuticals; an AmorChem start-up company.